ZEO ScientifiX

ZEO ScientifiX EBITDA per Employee

The EBITDA per Employee of ZEO ScientifiX (ZEOX) as of Nov 2, 2026 is -269,300.00 USD. In the previous year, EBITDA per Employee was -265,950.00 USD — a change of 1.26% (lower).

EBITDA per Employee

-269,300.00USD

YoY

1.26%

Last updated:

EBITDA per Employee of ZEO ScientifiX is 2025 -269,300.00 USD. EBITDA per Employee of ZEO ScientifiX was 2024 -265,950.00 USD. It decreases by 1.26% lower compared to the previous year.

The ZEO ScientifiX EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2017
-432,075.00 USD
Jan 1, 2018
-174,505.00 USD
Jan 1, 2020
-621,897.05 USD
Jan 1, 2021
-637,205.15 USD
Jan 1, 2022
-442,148.00 USD
Jan 1, 2023
-338,400.00 USD
Jan 1, 2024
-265,950.00 USD
Jan 1, 2025
-269,300.00 USD
The ZEO ScientifiX EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-269,300.00USD+1.26%
-265,950.00USD-21.41%
-338,400.00USD-23.46%
-442,148.00USD-30.61%
-637,205.15USD+2.46%
-621,897.05USD+256.38%
-174,505.00USD-59.61%
-432,075.00USD+728.29%
-52,165.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ZEO ScientifiX Stock analysis

What does ZEO ScientifiX do? Organicell Regenerative Medicine Inc generates revenue through its clinical-stage biopharmaceutical products, primarily focusing on regenerative medicine solutions. The company's leading product, Zofin (Organicell Flow), is an acellular biologic therapeutic derived from perinatal sources, containing over 300 growth factors, cytokines, chemokines, and 102 unique microRNAs. This product is administered through doctors and clinics in the healthcare industry, targeting degenerative diseases. The company has secured FDA approvals including IND and eIND, along with IRB authorizations, enabling its therapeutic applications. The company operates within the biotechnology sector, developing biological therapeutics for degenerative conditions. Zofin (Organicell Flow) serves as the core product, leveraging natural microRNAs and exosomes from perinatal tissues without additional substances. Healthcare providers and clinics are the primary buyers of this therapeutic, utilizing it for patient treatments under FDA-approved protocols. The product's unique composition supports its application in regenerative medicine, differentiating it in the market. Organicell Regenerative Medicine Inc's business model centers on the development and commercialization of Zofin (Organicell Flow), which is used in clinical settings for degenerative disease treatment. The company's focus on FDA-approved pathways through IND and eIND approvals ensures regulatory compliance for its product distribution. Healthcare professionals and clinics are the key segments purchasing the product, driven by its therapeutic benefits and natural composition derived from perinatal sources. ZEO ScientifiX is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ZEO ScientifiX stock

EBITDA per Employee of ZEO ScientifiX is -269,300.00 USD in 2025.

EBITDA per Employee of ZEO ScientifiX changed from -265,950.00 USD to -269,300.00 USD, representing a 1.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee ZEO ScientifiX since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's ZEO ScientifiX historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — ZEO ScientifiX

All Key Metrics — ZEO ScientifiX